HSTM vs. OMCL, MDRX, CRTX, UPWK, IQ, SIFY, SPT, UXIN, XNET, and YRD
Should you be buying HealthStream stock or one of its competitors? The main competitors of HealthStream include Omnicell (OMCL), Veradigm (MDRX), Cortexyme (CRTX), Upwork (UPWK), iQIYI (IQ), Sify Technologies (SIFY), Sprout Social (SPT), Uxin (UXIN), Xunlei (XNET), and Yirendai (YRD).
HealthStream vs. Its Competitors
Omnicell (NASDAQ:OMCL) and HealthStream (NASDAQ:HSTM) are both small-cap health care technology companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.
97.7% of Omnicell shares are held by institutional investors. Comparatively, 69.6% of HealthStream shares are held by institutional investors. 2.5% of Omnicell shares are held by insiders. Comparatively, 20.6% of HealthStream shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
HealthStream has a net margin of 6.89% compared to Omnicell's net margin of 2.01%. HealthStream's return on equity of 5.70% beat Omnicell's return on equity.
HealthStream has lower revenue, but higher earnings than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
In the previous week, HealthStream had 1 more articles in the media than Omnicell. MarketBeat recorded 1 mentions for HealthStream and 0 mentions for Omnicell. Omnicell's average media sentiment score of 1.00 beat HealthStream's score of 0.24 indicating that Omnicell is being referred to more favorably in the media.
Omnicell presently has a consensus target price of $46.71, suggesting a potential upside of 54.68%. HealthStream has a consensus target price of $31.00, suggesting a potential upside of 14.86%. Given Omnicell's higher probable upside, research analysts plainly believe Omnicell is more favorable than HealthStream.
Omnicell has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, HealthStream has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
Summary
HealthStream beats Omnicell on 9 of the 16 factors compared between the two stocks.
Get HealthStream News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSTM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
HealthStream Competitors List
Related Companies and Tools
This page (NASDAQ:HSTM) was last updated on 10/20/2025 by MarketBeat.com Staff